On October 5, 2026, GE HealthCare announced a definitive agreement to acquire SOFIE Biosciences from Trilantic North America.
Consello served as financial advisor to GE HealthCare on the transaction, which will establish a “final mile” footprint for PET radiopharmaceutical supply in the U.S., helping improve patient access, strengthen reliability of supply, and support the next generation of precision care.